Waters has now announced the selection of the St. John’s Research Institute for its Centres of Innovation Programme for research in the field of structural proteomics. It is the first institution in India to receive the designation of a Waters Centre of Innovation.

Under the direction of Prof. Amit Mandal, a Professor of Molecular Medicine and Clinical Proteomics, St. John’s is now recognised for its research in blood disorders and other diseases that disproportionately affect disadvantaged populations.

“Our relationship with Waters is not just one of a client and vendor; but as a  working partnership which has been so since this laboratory came into existence in 2009,” said K Srinivasan, dean, St. John’s Research Institute.

“Partnering with St. John’s Research Institute is a reflection of our mutual interests in serving society by improving the health of patient communities through science,” said KV Venugopalan, president, Waters India.

Prof. Mandal’s relationship with Waters began when he first began using a combination of a nano Acquity UPLC System and a Waters Synapt HDMS Mass Spectrometer equipped with an electrospray ionization source, a MALDI source, and an option for doing hydrogen deuterium exchange mass spectrometry (HDXMS).

“The instrumentation technology has helped to new insights into the structural changes associated with post-translational modifications of hemoglobin variant,” said Prof. Mandal.

St. Johns Research Institute is a part of the St John’s National Academy of Health Sciences, is dedicated to the pursuit of research and capacity development in medical research in India.

Waters Centres of Innovation Programme recognises and supports the efforts of scientists facilitating breakthroughs in health and life science research, food safety, environmental protection, sports medicine and many other areas. These included Professor Ganesh Anand, National University of Singapore; Professor David Clemmer, Indiana University, Bloomington, Indiana; Professor David Cowan, Kings College London; Dr Joseph Dalluge, University of Minnesota;  Professor Marcos Eberlin, University of Campinas, Brazil; Prof. Chris Elliott, Queen’s University Belfast, Northern Ireland; Professor John Engen, Northeastern University, Boston, Massachusetts; Professor Albert J Fornace, Jr., Georgetown Lombardi Comprehensive Cancer Centre, Washington, DC; Dr Frank Gonzalez, National Cancer Institute; Professor Julie Leary of the University of California – Davis; Dr Amit Kumar Mandal, St. John’s Research Institute, Bangalore, India; Professor Arthur Moseley of Duke University, Durham, North Carolina; Professor Jeremy Nicholson, Imperial College London; Dr Devin Peterson, University of Minnesota; Dr Konstantinos Petritis, Translational Genomics Research Institute, Phoenix, Arizona; Dr Ryan Rogers, Future Fuels Institute, Florida State University; Professor Pauline Rudd, National Institute for Bioprocessing Research and Training; Professor Vladimir Shulaev, University of North Texas; Professor James Scrivens, University of Warwick, Coventry, UK; Professor Sarah Trimpin, Wayne State University; Professor Bert van Bavel, Örebro University, Örebro, Sweden and Caroline West and Eric Lesselier, University of Orleans, Orleans, France.